Get Ready for a Trump 'Resurrection Run in 2024'

As the president continues to lie about the 2020 election being stolen from him, his aides are already discussing a Trump 2024 presidential run.

During a Thursday report on CNN, White House Correspondent Jim Acosta said aides to the Trump campaign have already raised the topic of a “resurrection run in 2024” with the president.

“There are some aides and advisers who are starting to talk about the potential not only that the president is going to lose this election, but that he may mount some sort of resurrection run in 2024,” Acosta said, adding, “Some have even talked about it with the president himself.”

Acosta went on to explain that the talk of a 2024 Trump run points to a “growing pessimism inside the campaign” regarding the current vote count. And one Trump campaign advisor told CNN that it’s “looking increasingly bleak in Georgia for the president.”

Acosta made it clear that despite the pessimism in Trump’s camp, the president has not given up on winning the current election and is trying to “gin up enough outrage out there… to change the outcome.”

Like a horror movie murderer who just won’t die, the brutal reality of a Trump who refuses to go quietly always seemed like a certainty. So now, before the curtain has officially dropped on the awful original, it appears a sequel may already be in the works.

Herald morning quiz: November 6

Test your brains with the Herald's morning quiz. Be sure to check back on nzherald.co.nz at 3pm for the afternoon quiz.

Chinese yuan finishes domestic session at 28-month closing high

SHANGHAI, Nov 5 (Reuters) – China’s onshore spot yuan finished its domestic trading session at 6.64 per dollar on Thursday, its strongest close since July 10, 2018.

US election 2020: Trump v Biden too early to call

The votes are still coming in, and America hasn’t picked a president – where do we go from here?

US correspondent Cordelia Lynch and Washington bureau chief Emily Purser Brown bring you this episode of Divided States from a tented roof in Washington DC to unpick the key moments of election night and debate the potential paths to victory for both Joe Biden and Donald Trump in the hours and days ahead.

:: Subscribe to Divided States on Apple podcasts, Google Podcasts, Spotify, and Spreaker

A Big Win for Democrats in California Came With a Gut Check for Liberals

Joe Biden received one of the highest margins in the nation in California, but a look at how the state’s ballot measures were decided shows a more complex picture of the electorate.

By Thomas Fuller, Shawn Hubler, Tim Arango and Conor Dougherty

Pappas Capital’s VelosBio To Be Acquired By Merck In $2.75 Bln Cash Deal

Pappas Capital announced Thursday that that its portfolio company, VelosBio Inc., has entered into a definitive agreement to be acquired by a subsidiary of Merck (MRK) for $2.75 billion in cash, subject to customary adjustments.

VelosBio is a clinical-stage biopharmaceutical company, developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 or ROR1.

The venture capital firm focused on advancing life sciences first invested in VelosBio in 2018 as part of the Company’s $58 million Series A financing. Pappas Capital subsequently participated in the company’s $137 million Series B financing in July 2020.

Pappas Managing Partner Kyle Rasbach has served as a VelosBio Board Observer, providing hands-on support and guidance on the development of VelosBio’s investigational candidate (VLS-101).

VLS-101 is an antibody-drug conjugate (ADC) targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively.

VelosBio is Pappas Ventures V’s second exit this year. Curzion Pharmaceuticals, Inc., a company co-founded by Pappas Capital, was acquired by Horizon Therapeutics plc in April 2020.

France says its faith in U.S. institutions validating vote results

PARIS (Reuters) – France’s foreign minister said on Thursday he had faith good sense would prevail in the U.S. election and that its strong democratic values would ensure the correct results.

“I have faith in U.S. institutions validating the results of the election,” Jean-Yves Le Drian told Europe 1 radio.

AstraZeneca: Forxiga Gets EU Approval For Heart Failure – Quick Facts

AstraZeneca Plc. (AZN.L,AZN) Thursday announced that its Forxiga (dapagliflozin) has been approved in the European Union for the treatment of symptomatic chronic heart failure with reduced ejection fraction or HFrEF in adults with and without type-2 diabetes.

Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes.

The EU approval is based on positive results from the landmark DAPA-HF Phase III trial, published in The New England Journal of Medicine .7 It follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

The company noted that Forxiga is the first sodium-glucose co-transporter-2 or SGLT2 inhibitor to have shown a statistically significant reduction in the risk of the composite of cardiovascular death or worsening of HF events.

Forxiga, known as Farxiga in the US, is already approved in the US for the treatment of patients with HFrEF and is currently under review in Japan and in several over countries around the world.